It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Crosstalk between liver and skeletal muscle is vital for glucose homeostasis. Hepatokines, liver-derived proteins that play an important role in regulating muscle metabolism, are important to this communication. Here we identify apolipoprotein J (ApoJ) as a novel hepatokine targeting muscle glucose metabolism and insulin sensitivity through a low-density lipoprotein receptor-related protein-2 (LRP2)-dependent mechanism, coupled with the insulin receptor (IR) signaling cascade. In muscle, LRP2 is necessary for insulin-dependent IR internalization, an initial trigger for insulin signaling, that is crucial in regulating downstream signaling and glucose uptake. Of physiologic significance, deletion of hepatic ApoJ or muscle LRP2 causes insulin resistance and glucose intolerance. In patients with polycystic ovary syndrome and insulin resistance, pioglitazone-induced improvement of insulin action is associated with an increase in muscle ApoJ and LRP2 expression. Thus, the ApoJ-LRP2 axis is a novel endocrine circuit that is central to the maintenance of normal glucose homeostasis and insulin sensitivity.
Hepatokines are proteins secreted by the liver that can regulate whole body metabolism. Here the authors identify apolipoprotein J as a hepatokine that regulates muscle glucose metabolism and insulin resistance through a low-density lipoprotein receptor-related protein−2 mediated mechanism in mice.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details














1 Beth Israel Deaconess Medical Center and Harvard Medical School, Division of Endocrinology, Diabetes, and Metabolism, Boston, USA (GRID:grid.239395.7) (ISNI:0000 0000 9011 8547); Korea University College of Medicine, Division of Endocrinology, Department of Internal Medicine, Seoul, Korea (GRID:grid.222754.4) (ISNI:0000 0001 0840 2678)
2 Beth Israel Deaconess Medical Center and Harvard Medical School, Division of Endocrinology, Diabetes, and Metabolism, Boston, USA (GRID:grid.239395.7) (ISNI:0000 0000 9011 8547); Korea Food Research Institute, Research Group of Food Processing, Wanju-gun, Korea (GRID:grid.418974.7) (ISNI:0000 0001 0573 0246)
3 Beth Israel Deaconess Medical Center and Harvard Medical School, Division of Endocrinology, Diabetes, and Metabolism, Boston, USA (GRID:grid.239395.7) (ISNI:0000 0000 9011 8547); Seoul National University, Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology, Seoul, Korea (GRID:grid.31501.36) (ISNI:0000 0004 0470 5905)
4 Beth Israel Deaconess Medical Center and Harvard Medical School, Division of Endocrinology, Diabetes, and Metabolism, Boston, USA (GRID:grid.239395.7) (ISNI:0000 0000 9011 8547); Konyang University, Division of Nephrology, Department of Internal Medicine, College of Medicine, Daejeon, Korea (GRID:grid.411143.2) (ISNI:0000 0000 8674 9741)
5 Beth Israel Deaconess Medical Center and Harvard Medical School, Division of Endocrinology, Diabetes, and Metabolism, Boston, USA (GRID:grid.239395.7) (ISNI:0000 0000 9011 8547); Pusan National University Hospital, Department of Internal Medicine and Biomedical Research Institute, Busan, Korea (GRID:grid.412588.2) (ISNI:0000 0000 8611 7824)
6 Beth Israel Deaconess Medical Center and Harvard Medical School, Division of Endocrinology, Diabetes, and Metabolism, Boston, USA (GRID:grid.239395.7) (ISNI:0000 0000 9011 8547); Columbia University, New York, USA (GRID:grid.21729.3f) (ISNI:0000000419368729)
7 Korea University College of Medicine, Division of Endocrinology, Department of Internal Medicine, Seoul, Korea (GRID:grid.222754.4) (ISNI:0000 0001 0840 2678)
8 Beth Israel Deaconess Medical Center and Harvard Medical School, Division of Endocrinology, Diabetes, and Metabolism, Boston, USA (GRID:grid.239395.7) (ISNI:0000 0000 9011 8547)
9 Beth Israel Deaconess Medical Center and Harvard Medical School, Division of Endocrinology, Diabetes, and Metabolism, Boston, USA (GRID:grid.239395.7) (ISNI:0000 0000 9011 8547); University of Campinas, School of Applied Science, Limeira, Brazil (GRID:grid.411087.b) (ISNI:0000 0001 0723 2494)
10 Beth Israel Deaconess Medical Center and Harvard Medical School, Division of Endocrinology, Diabetes, and Metabolism, Boston, USA (GRID:grid.239395.7) (ISNI:0000 0000 9011 8547); East Carolina Diabetes and Obesity Institute, East Carolina University, Greenville, USA (GRID:grid.255364.3) (ISNI:0000 0001 2191 0423)
11 Beth Israel Deaconess Medical Center and Harvard Medical School, Division of Endocrinology, Diabetes, and Metabolism, Boston, USA (GRID:grid.239395.7) (ISNI:0000 0000 9011 8547); The Catholic University of Korea, College of Medicine, Seoul, Korea (GRID:grid.411947.e) (ISNI:0000 0004 0470 4224)
12 Beth Israel Deaconess Medical Center and Harvard Medical School, Division of Endocrinology, Diabetes, and Metabolism, Boston, USA (GRID:grid.239395.7) (ISNI:0000 0000 9011 8547); Universidade Nova de Lisboa, Lisboa, Portugal (GRID:grid.10772.33) (ISNI:0000000121511713)
13 Seoul National University, Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology, Seoul, Korea (GRID:grid.31501.36) (ISNI:0000 0004 0470 5905)
14 University of Ulsan, College of Medicine, Department of Internal Medicine, Asan Medical Center, Seoul, Korea (GRID:grid.267370.7) (ISNI:0000 0004 0533 4667)
15 Max-Delbrueck-Center for Molecular Medicine, Molecular Cardiovascular Research, Berlin, Germany (GRID:grid.419491.0) (ISNI:0000 0001 1014 0849)
16 Veterans Affairs San Diego Healthcare System (9111 G), San Diego, USA (GRID:grid.410371.0) (ISNI:0000 0004 0419 2708); University of California San Diego, Department of Medicine, La Jolla, USA (GRID:grid.266100.3) (ISNI:0000 0001 2107 4242); Brigham and Women’s Hospital and Harvard Medical School, Boston, USA (GRID:grid.62560.37) (ISNI:0000 0004 0378 8294)
17 Veterans Affairs San Diego Healthcare System (9111 G), San Diego, USA (GRID:grid.410371.0) (ISNI:0000 0004 0419 2708); University of California San Diego, Department of Medicine, La Jolla, USA (GRID:grid.266100.3) (ISNI:0000 0001 2107 4242)